By Fineline Cube Alphamab Oncology (HKG: 9966) announced that the Phase III KN026-004 clinical study evaluating anbenitamab in combination with docetaxel injection (albumin-bound) (HB1801) for neoadjuvant treatment of HER2-positive breast cancer successfully met its pre-specified primary endpoint, demonstrating significant improvement in total pathological complete response (tpCR) versus current standard of care.
Clinical Trial Results
| Parameter | Detail |
|---|---|
| Study Designation | KN026-004 Phase III |
| Patient Population | HER2-positive breast cancer (neoadjuvant setting) |
| Treatment Arm | Anbenitamab + albumin-bound docetaxel (HB1801) |
| Comparator | Current standard of care |
| Primary Endpoint | Total pathological complete response (tpCR) |
| Result | Statistically significant improvement achieved |
Drug Profile & Development Status
Anbenitamab Characteristics
- Type: Bispecific antibody (BsAb) targeting HER2
- Mechanism: Dual HER2 targeting for enhanced anti-tumor activity
- Indications: HER2+ breast cancer and gastric cancer/gastroesophageal junction cancer
- Regulatory Status:
- NDA under review by NMPA (accepted September 2025)
- FDA Orphan Drug Designation for HER2+ or HER2-low gastric cancer
- NMPA Breakthrough Therapy Designation for second-line+ HER2+ gastric cancer
Commercial Partnership
- Licensee: CSPC subsidiary Shanghai JMT Biotechnology
- Territory: Mainland China exclusive rights
- Indications Covered: Breast and gastric cancers
- Deal Year: 2021 licensing agreement
Regulatory Milestones Timeline
| Agency | Designation | Indication | Status |
|---|---|---|---|
| NMPA | New Drug Application | HER2+ breast cancer | Under review (accepted Sep 2025) |
| NMPA | Breakthrough Therapy | HER2+ gastric/GEJ cancer (2L+) | Granted |
| FDA | Orphan Drug Designation | HER2+ or HER2-low gastric cancer | Granted |
Strategic Significance
For Alphamab Oncology
- Pipeline Validation: Phase III success validates bispecific antibody platform
- Commercial Upside: Royalty stream from CSPC partnership upon approval
- Global Potential: Strong clinical data supports potential international expansion
- Platform Technology: Demonstrates capability to develop differentiated HER2-targeting biologics
For CSPC/Shanghai JMT
- Market Opportunity: First-in-class bispecific antibody for HER2+ breast cancer in China
- Competitive Advantage: Differentiated mechanism versus existing HER2 therapies
- Revenue Potential: Premium pricing expected for novel bispecific approach
- Strategic Asset: Key oncology asset in growing Chinese biologics market
Market Context & Competitive Landscape
- HER2+ Breast Cancer: Represents 15-20% of all breast cancer cases globally
- Neoadjuvant Setting: Critical treatment window where tpCR strongly correlates with long-term survival
- Current Standard: Trastuzumab-based regimens dominate but leave room for improvement
- Bispecific Innovation: Novel approach combining two HER2 epitopes for enhanced efficacy
- Chinese Market: Rapidly growing oncology market with increasing adoption of premium biologics
Next Steps & Commercial Outlook
- NDA Review: Expected approval decision from NMPA in 2026
- Launch Preparation: CSPC likely preparing commercial infrastructure for rapid market entry
- Additional Indications: Potential expansion into adjuvant and metastatic settings
- International Strategy: Possible global partnerships following Chinese approval
Forward‑Looking Statements
This brief contains forward-looking statements regarding clinical trial results, regulatory approvals, and commercial potential for anbenitamab. Actual results may differ due to risks including regulatory decisions, competitive dynamics, and market acceptance.-Fineline Info & Tech